Nemi Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 40 Year, 7 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.17 Cr
- Revenue Growth 3.12%
- Profit Growth 14.03%
- Ebitda 17.80%
- Net Worth 5.59%
- Total Assets 7.89%
About Nemi Pharma
Nemi Pharma Pvt Ltd (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 February 1985 and has a history of 40 years. Its registered office is in Vasai, Maharashtra.
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹6.17 Cr.
Lalit Talati and Saroj Talati serve as directors at the Company.
Company Details
- Location Vasai, Maharashtra
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1985PTC035276
-
Company No.
035276
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Feb 1985
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nemi Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalit Talati
|
Director | 06-Feb-1985 | Current |
|
Saroj Talati
|
Director | 06-Feb-1985 | Current |
Financial Performance of Nemi Pharma.
Nemi Pharma Pvt Ltd, for the financial year ended 2022, experienced modest growth in revenue, with a 3.12% increase. The company also saw a substantial improvement in profitability, with a 14.03% increase in profit. The company's net worth moved up by a moderate rise of 5.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nemi Pharma?
In 2020, Nemi Pharma had a promoter holding of 38.64% and a public holding of 61.36%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nem Laboratories Pvt LtdLalit Talati is a mutual person
Charges (Loans)
₹61.70 M
₹0
Charges Breakdown by Lending Institutions
- Others : 5.30 Cr
- Canara Bank : 0.87 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Jun 1996 | Canara Bank | ₹0.50 M | Open |
| 26 Sep 1994 | Others | ₹5.30 Cr | Open |
| 26 Apr 1994 | Canara Bank | ₹1.10 M | Open |
| 26 Apr 1993 | Canara Bank | ₹1.10 M | Open |
| 03 Mar 1992 | Canara Bank | ₹0.80 M | Open |
How Many Employees Work at Nemi Pharma?
Nemi Pharma has a workforce of 2 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nemi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nemi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
